Fucoidan (Brown Seaweed Polysaccharide)
Fucoidan is a family of sulfated polysaccharides, long sugar chains built mostly from fucose, found in brown seaweeds such as wakame (Undaria), bladderwrack (Fucus), kombu (Laminaria) and mozuku (Cladosiphon). It is not one fixed molecule: chain length, sulfate content and other sugars vary with species and extraction method, so results from one product do not carry over automatically. Human trials are small, and many tested Maritech extracts from the Australian maker Marinova, which funded them. A Japanese maker's wakame fucoidan raised antibody response to a flu vaccine in older adults, and a Marinova extract lowered urinary symptom scores in men. Blood sugar results were inconsistent, a 12-week trial found lower inflammatory markers than placebo, and a placebo-controlled joint trial found no benefit. Seaweed-based products can carry iodine and arsenic, so tested products matter.
Benefits
Antibody response to seasonal flu vaccination in older adults
In a placebo-controlled trial in 70 adults over 60 living in a nursing home in Japan, 300 mg a day of wakame sporophyll fucoidan from a Japanese maker (Riken Mekabu Fucoidan, in a self-funded study), started 4 weeks before a flu shot, led to higher antibody levels against all three vaccine strains. Flu cases were not counted, and the result has not been repeated.
Natural killer cell activity in healthy adults
In a placebo-controlled pilot in 40 healthy adults, with material supplied by the maker, 3 g a day of mozuku fucoidan raised natural killer cell activity at 8 weeks versus baseline, but beat placebo only in men. In a small crossover exercise trial funded by Marinova, 1 g a day of its wakame fucoidan made little difference to most blood immune markers. These are marker-level findings.
Prostate health and urinary symptom scores in men
In one 90-day placebo-controlled trial in 95 men aged 45 to 80 with moderate prostate enlargement, 1 g a day of a Marinova wakame fucoidan lowered a urinary symptom score by 3.40 points versus 0.93 on placebo. Urine flow, leftover urine and PSA did not differ. Marinova funded the trial and supplied the product, and two authors worked for it. Urinary symptoms need a medical check first.
Blood sugar and insulin markers
At 1 g a day of Marinova's Maritech Synergy for 90 days, insulin resistance did not change versus placebo in 72 adults with obesity. In 70 adults with prediabetes, glycated serum protein, a short-term blood sugar marker, rose less than on placebo over 12 weeks; it is the only blood sugar measure the abstract reports as differing. Smaller trials found a slight HbA1c drop in a diabetes subgroup and higher insulin in another.
Stool frequency and gut bacteria markers
In a crossover trial in adults with diet-treated type 2 diabetes, stool frequency rose from about 8 to 9 a week on fucoidan, a before and after change, not a gap versus placebo. A prediabetes trial reported shifts in some gut bacteria versus placebo, and an open-label trial in patients on drug therapy for H. pylori found more beneficial bacteria kept. Small trials of markers, not symptoms in healthy people.
Joint comfort and stiffness
In an open-label pilot in 12 adults with knee osteoarthritis, a three-seaweed Maritech blend (mostly Fucus) with vitamin B6, zinc and manganese lowered a symptom score, more at 1,000 mg than 100 mg a day. But in a placebo-controlled trial in 122 adults with hip or knee osteoarthritis, 300 mg a day of a Marinova Fucus extract for 12 weeks did no better than placebo. Marinova sponsored both.
Blood inflammatory markers
In a 12-week placebo-controlled trial in 70 adults with prediabetes, 1,000 mg a day of fucoidan lowered blood TNF-alpha, IL-6 and LPS compared with placebo. In a Marinova-funded crossover trial in active adults, interleukin-6 and interleukin-10 were higher, not lower, 30 minutes after hard exercise. These are blood markers from small trials, not symptoms.
Mechanism of action
Sulfated sugar chains that differ by source
Fucoidan is a backbone of fucose units carrying sulfate groups, usually with smaller amounts of other sugars. The sulfation pattern, sugar mix and chain length change with species and extraction, which is why fucoidan extracts are not interchangeable and why reproducible, quality-controlled production has been hard.
Limited absorption from the gut
Fucoidan is a large polysaccharide and little of it appears to be absorbed. In a pilot study, a strong anticoagulant effect seen in the test tube was much weaker after 3 g a day by mouth, which the researchers attributed to low intestinal absorption. Much of any effect may therefore start in the gut and its bacteria.
Immune cell signaling (lab and animal work)
In cell and animal studies, fucoidan interacts with macrophages, dendritic cells and natural killer cells and alters cytokine release. These are proposed explanations for the small changes in human immune markers, not mechanisms confirmed in people.
Heparin-like activity in the test tube
Like heparin, sulfated fucoidan lengthens several clotting times in laboratory tests. Taken by mouth the effect is far weaker, but one clotting time did lengthen in a small study, which is why it matters for people on blood thinners.
Clinical trials
Randomized, double-blind, placebo-controlled trial of 300 mg/day Riken Mekabu Fucoidan (Riken Vitamin; from the sporophyll of Undaria pinnatifida) in granules with dextrin, for 4 weeks before seasonal flu vaccination and 24 weeks in all; self-funded, and not a Marinova product (Negishi et al. 2013, J Nutr).
70 adults over 60 living in a nursing home in Osaka, Japan. Five died of old age or illness and several others left after hospital stays; the doctors judged none of these related to the product.
The fucoidan group had higher antibody titers than placebo against all three vaccine strains, with the clearest gain against the B strain. Natural killer cell activity only tended to rise (P = 0.08). The trial measured antibodies, not flu illness, and has not been replicated.
Randomized, double-blind, parallel-group, placebo-controlled pilot of 3 g/day Cladosiphon okamuranus (Okinawa mozuku) fucoidan in a drink for 12 weeks; material supplied by the maker, which paid two authors (Tomori et al. 2021, Mar Drugs).
40 healthy Japanese adults (20 fucoidan, 20 placebo), average age about 46.
NK cell activity rose significantly at week 8 compared with baseline in the fucoidan group. Against placebo the difference was significant only in men at week 8. No adverse events were attributed to the drink. A small pilot with a marker outcome.
Randomized, double-blind, placebo-controlled trial of 1 g/day Undaria pinnatifida fucoidan (two 500 mg capsules; batch tested at 85.5% fucoidan) made and supplied by Marinova, which funded the trial; two authors were Marinova employees when it was planned and run (Wimmer et al. 2026, Res Rep Urol).
95 men aged 45 to 80 in India with moderate benign prostatic hyperplasia (symptom score 8 to 19).
The International Prostate Symptom Score fell 3.40 points with fucoidan versus 0.93 with placebo by day 90, with better voiding, storage and quality-of-life scores. Urinary flow rate, residual urine volume and PSA did not differ between groups. Adverse events were similar in number to placebo (12 vs 10). A single sponsor-funded trial.
Single-site, double-blind, placebo-controlled trial of 500 mg twice daily for 90 days; the registry (ACTRN12614000495628) names the product Maritech Synergy, a Fucus vesiculosus extract; funded by Marinova, and two authors (Fitton, Stringer) were from Marinova. Primary outcome insulin resistance (HOMA); HbA1c, lipids, weight, waist and blood pressure also did not differ (Wright et al. 2019, J Altern Complement Med).
72 adults with obesity aged 18 to 65 without diabetes in Tasmania, Australia (35 fucoidan, 37 placebo).
No difference from placebo in the primary outcome (mean HOMA change 0 on placebo and -0.1 on fucoidan, p = 0.73) or in any secondary outcome. The authors list possible reasons, including short duration, adherence and low baseline values.
Randomized, double-blind, placebo-controlled trial of 1,000 mg/day fucoidan capsules for 12 weeks (Liu et al. 2025, Int J Biol Macromol).
70 Chinese adults with prediabetes.
Glycated serum protein, a short-term blood sugar marker, rose less on fucoidan than on placebo, and TNF-alpha, IL-6 and LPS fell. Stool samples showed more Megamonas and Blautia and less Klebsiella. The authors call the effect on glucose metabolism partial; outcomes were lab markers, not diabetes onset.
Double-blind, randomized, placebo-controlled trial of 300 mg/day of a Marinova Fucus vesiculosus extract (85% fucoidan in the abstract; 88.5% w/w in the full text; capsules of 150 mg extract) for 12 weeks; sponsored by Marinova, which supplied the capsules and employed author J. H. Fitton (Myers et al. 2016, Biologics).
122 adults with mild-to-moderate hip or knee osteoarthritis; 96 completed.
Symptom reduction on the Comprehensive Osteoarthritis Test did not differ from placebo. Blood safety tests showed no clinically meaningful changes. This followed a 12-person open-label pilot of a Marinova seaweed blend with added nutrients that had reported dose-related improvement.
Single-blind pilot of 3 g/day of 75% fucoidan capsules versus guar gum placebo for 12 days, with clotting tests and test-tube anticoagulant assays (Irhimeh et al. 2009, Blood Coagul Fibrinolysis).
20 adult volunteers (10 fucoidan, 10 placebo).
Activated partial thromboplastin time rose from 28.41 to 34.01 seconds and thrombin time fell slightly. In the test tube fucoidan was a strong anticoagulant, but the authors concluded the effect after swallowing it was not obvious, probably because little is absorbed.
Randomized, double-blind, placebo-controlled, counterbalanced crossover of 1 g/day Undaria pinnatifida fucoidan in 500 mg capsules produced by Marinova, for 2 weeks per period; funded by Marinova, although the conflict-of-interest statement declares none. Most blood immune markers did not differ by condition (McFadden et al. 2023, J Int Soc Sports Nutr).
16 recreationally active adults (8 men, 8 women).
Exercise performance and most blood markers did not differ by condition. Interleukin-6 and interleukin-10 were higher 30 minutes after exercise on fucoidan. No adverse events were reported.
Side effects and drug interactions
Common Potential side effects
Important Drug interactions
Frequently asked questions about Fucoidan (Brown Seaweed Polysaccharide)
Is fucoidan the same as fucoxanthin?
No. Both come from brown seaweeds, but fucoidan is a sulfated sugar chain (a fiber-like polysaccharide), while fucoxanthin is an orange carotenoid pigment studied mainly for body weight. They are sold separately and have different research. See our fucoxanthin page.
Are all fucoidan supplements the same?
No. Fucoidan from wakame, bladderwrack, kombu or mozuku differs in sulfate content, chain size and other sugars, and extraction methods change it further. The trials used specific extracts at 300 mg to 3 g a day, so a result from one product does not prove another will act the same.
Does fucoidan contain iodine?
It depends on the raw seaweed and how far the extract is purified. Seaweed supplements in one market survey supplied up to 5,600 micrograms of iodine per daily dose, well above the adult upper limit, and labels were often inaccurate. If you have a thyroid condition, ask the maker for a recent iodine test.
What does the prostate research on fucoidan show?
One placebo-controlled trial in men with moderate prostate enlargement found lower urinary symptom scores with 1 g a day of wakame fucoidan, but urine flow and PSA did not change and Marinova, which makes the extract, funded it. Urinary symptoms can have serious causes, so see a doctor for a diagnosis and do not replace prescribed treatment.
Which fucoidan products were used in the human trials?
Several. The urinary symptom, insulin resistance, joint and exercise trials used Maritech extracts from the Australian maker Marinova, which funded them. The flu vaccine trial used Riken Mekabu Fucoidan from a Japanese maker, and the natural killer cell pilot used Okinawa mozuku fucoidan supplied by its maker. A result from one product does not automatically carry over to another.
What is Fucoidan?
Fucoidan is a family of sulfated polysaccharides, long sugar chains built mostly from fucose, found in brown seaweeds such as wakame (Undaria), bladderwrack (Fucus), kombu (Laminaria) and mozuku (Cladosiphon).
What is Fucoidan used for?
Fucoidan is researched primarily for Immune Support, Prostate Health, and Metabolic Health. In a placebo-controlled trial in 70 adults over 60 living in a nursing home in Japan, 300 mg a day of wakame sporophyll fucoidan from a Japanese maker (Riken Mekabu Fucoidan, in a self-funded study), started 4 weeks before a flu shot, led t…
What is the recommended dosage of Fucoidan?
The clinically studied dose is 300 mg/day (vaccine trial); 500 mg to 1 g/day (blood sugar, urinary symptom and exercise trials); 1,620 mg/day (diabetes trial); 3 g/day (NK cell trial). Trials lasted 12 days to 24 weeks. Always follow the product label and check with a healthcare provider for personal advice.
Is Fucoidan safe, and does it have side effects?
Side effects and cautions reported for Fucoidan include: In trials of 300 mg to about 3 g a day for up to 24 weeks, few adverse events were reported; in the 90-day trial in men they numbered 12 on fucoidan and 10 on placebo. In a 2-week study, 20 people taking up to 4.05 g a day had no abnormal blood or urine results. It may also interact with some medications. Fucoidan is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.
Does Fucoidan interact with any medications?
Possible interactions include: Anticoagulants and antiplatelet drugs (warfarin, DOACs, heparin, clopidogrel, aspirin): possible added bleeding risk; ask your prescriber. Thyroid medicines (levothyroxine, methimazole, propylthiouracil): iodine in seaweed-derived products can disturb thyroid control. If you take prescription medication, check with a pharmacist or doctor before using it.
How strong is the scientific evidence for Fucoidan?
NutraSmarts rates the evidence for Fucoidan as Limited (2 out of 5). It is backed by 8 study summaries and 16 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.
References(16 citations)
Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.
- Supplementation of elderly Japanese men and women with fucoidan from seaweed increases immune responses to seasonal influenza vaccination. J Nutr. 2013;143(11):1794-8. doi: 10.3945/jn.113.179036.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 70 Japanese adults over 60 living in a nursing home: 300 mg/day of mekabu fucoidan (from the sporophyll of wakame, Undaria pinnatifida), started 4 weeks before a trivalent flu vaccine and taken for 24 weeks in all, gave higher antibody titers against all three vaccine strains than placebo, measured 5 and 20 weeks after vaccination. Natural killer cell activity only tended to rise (P = 0.08). Flu illness was not measured. The full text names the product as Riken Mekabu Fucoidan (Riken Vitamin), not a Marinova extract; the project was self-funded.
- Effects of Ingesting Fucoidan Derived from Cladosiphon okamuranus Tokida on Human NK Cells: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Pilot Study. Mar Drugs. 2021;19(6):340. doi: 10.3390/md19060340.PubMedUsed to support: Randomized, double-blind, placebo-controlled pilot in 40 healthy Japanese adults: 3 g/day of Okinawa mozuku (Cladosiphon okamuranus) fucoidan in a drink for 12 weeks raised natural killer cell activity at week 8 compared with baseline; compared with placebo the difference was significant only in men at week 8. No adverse events from the test drink. Two authors were paid by the fucoidan supplier, which provided the material.
- Effects of fucoidan supplementation on inflammatory and immune response after high-intensity exercise. J Int Soc Sports Nutr. 2023;20(1):2224751. doi: 10.1080/15502783.2023.2224751.PubMedUsed to support: Randomized, double-blind, placebo-controlled crossover in 16 active adults given 1 g/day of Undaria pinnatifida fucoidan: no effect on exercise performance or on most blood immune markers after sprint exercise; interleukin-6 and interleukin-10 were higher, not lower, 30 minutes after exercise. No adverse events. Funded by the fucoidan maker Marinova, which produced the capsules.
- Fucoidan from Undaria pinnatifida Improves Benign Prostatic Hyperplasia Symptoms in Men: A Randomized, Double-Blind, Placebo-Controlled Study. Res Rep Urol. 2026;18:597883. doi: 10.2147/RRU.S597883.PubMedUsed to support: Randomized, double-blind, placebo-controlled 90-day trial in 95 men aged 45 to 80 with moderate benign prostatic hyperplasia in India: 1 g/day of Undaria pinnatifida fucoidan (two 500 mg capsules) lowered the International Prostate Symptom Score by 3.40 points versus 0.93 on placebo, with better voiding, storage and urinary quality-of-life scores. Urinary flow rate, residual urine volume and PSA did not differ between groups. Marinova funded the trial and made and supplied the product (batch tested at 85.5% fucoidan); two authors were Marinova employees when it was planned and conducted. A single trial.
- Effect of a Fucoidan Extract on Insulin Resistance and Cardiometabolic Markers in Obese, Nondiabetic Subjects: A Randomized, Controlled Trial. J Altern Complement Med. 2019;25(3):346-352. doi: 10.1089/acm.2018.0189.PubMedUsed to support: Double-blind, placebo-controlled trial in 72 obese adults without diabetes in Tasmania: 500 mg of fucoidan twice daily for 90 days did not change insulin resistance (HOMA, p = 0.73) or other cardiometabolic markers, including HbA1c, lipids, weight and blood pressure. Funded by Marinova; two authors were from Marinova. The registry entry (ACTRN12614000495628) names the product as Maritech Synergy, a Fucus vesiculosus extract.
- Effect of fucoidan administration on insulin secretion and insulin resistance in overweight or obese adults. J Med Food. 2014;17(7):830-2. doi: 10.1089/jmf.2013.0053.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 25 overweight or obese adults: after 500 mg/day of fucoidan for 3 months, diastolic blood pressure and LDL cholesterol were lower and insulin levels and an index of insulin secretion were higher than at the start, but the insulin-resistance index (HOMA-IR) also rose. These are before and after changes within the fucoidan group. Very small trial.
- Effect of fucoidan supplementation on glycolipid metabolism, systemic inflammation and gut microbiota in prediabetes: A randomized controlled trial. Int J Biol Macromol. 2025;287:138415. doi: 10.1016/j.ijbiomac.2024.138415.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 70 Chinese adults with prediabetes: 1,000 mg/day of fucoidan for 12 weeks led to a smaller rise in glycated serum protein (a short-term blood sugar marker) and lower TNF-alpha, IL-6 and LPS than placebo, with more Megamonas and Blautia and less Klebsiella in stool samples. Markers only; the authors describe the effect on glucose metabolism as partial.
- A Randomized Placebo-controlled Trial of an Oral Preparation of High Molecular Weight Fucoidan in Patients with Type 2 Diabetes with Evaluation of Taste Sensitivity. Yonago Acta Med. 2019;62(1):14-23. doi: 10.33160/yam.2019.03.003.PubMedUsed to support: Randomized, double-blind, placebo-controlled crossover in 30 adults with diet-treated type 2 diabetes: a drink supplying 1,620 mg/day of high-molecular-weight fucoidan for 12 weeks increased stool frequency (about 7.8 to 9.2 per week) and, in a subgroup of 14 without insulin resistance, HbA1c fell slightly (6.73% to 6.59%). These are within-group and subgroup changes. Two authors were from a seaweed products company. No adverse events.
- Effect of fucoidan on gut microbiota and its clinical efficacy in Helicobacter pylori eradication: A randomized controlled trial. J Dig Dis. 2023;24(8-9):461-471. doi: 10.1111/1751-2980.13215.PubMedUsed to support: Open-label randomized trial in 90 Chinese patients with H. pylori infection receiving standard quadruple drug therapy: adding fucoidan, especially when started before the drug course, kept more beneficial gut bacteria (including Bifidobacterium) than drug therapy alone, and the authors reported greater relief of digestive symptoms. No placebo; two authors were from a seaweed company. Patients under medical treatment.
- A combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis. Biologics. 2010;4:33-44. doi: 10.2147/btt.s8354.PubMedUsed to support: Open-label pilot in 12 adults with knee osteoarthritis given 100 mg or 1,000 mg/day of a Maritech blend (85% Fucus vesiculosus, 10% Macrocystis pyrifera, 5% Laminaria japonica extract) plus vitamin B6, zinc and manganese for 12 weeks: an arthritis symptom score fell 18% on the lower dose and 52% on the higher dose. No placebo group; a multi-ingredient product. The authors reported it was well tolerated. Sponsored by Marinova, which employed author J. H. Fitton.
- Effects of fucoidan from Fucus vesiculosus in reducing symptoms of osteoarthritis: a randomized placebo-controlled trial. Biologics. 2016;10:81-8. doi: 10.2147/BTT.S95165.PubMedUsed to support: Double-blind, placebo-controlled trial in 122 adults with mild-to-moderate hip or knee osteoarthritis (96 completed): 300 mg/day of a Marinova Fucus vesiculosus extract (85% fucoidan in the abstract; 88.5% w/w in the full text, given as capsules of 150 mg extract) for 12 weeks did not reduce symptoms more than placebo. The authors concluded it was safe and well tolerated over 12 weeks, with no clinically meaningful blood changes. Sponsored by Marinova, which supplied the capsules; author J. H. Fitton was a Marinova employee.
- Pilot clinical study to evaluate the anticoagulant activity of fucoidan. Blood Coagul Fibrinolysis. 2009;20(7):607-10. doi: 10.1097/MBC.0b013e32833135fe.PubMedUsed to support: Single-blind pilot in 20 volunteers: 3 g/day of 75% fucoidan for 12 days lengthened activated partial thromboplastin time (28.41 to 34.01 seconds) and slightly changed thrombin time and antithrombin-III. Fucoidan was a strong anticoagulant in the test tube, but the authors judged its effect in the body not obvious, probably because little is absorbed from the gut.
- Safety evaluation of excessive ingestion of mozuku fucoidan in human. J Food Sci. 2013;78(4):T648-51. doi: 10.1111/j.1750-3841.2012.02966.x.PubMedUsed to support: Safety study in 20 people taking mozuku fucoidan at up to 4.05 g/day for 2 weeks: no disorders, and no abnormal abdominal, stool, blood or urine findings; total and LDL cholesterol fell slightly but stayed within normal ranges. Short and small; the first author is from a seaweed products company.
- Commercially available kelp and seaweed products - valuable iodine source or risk of excess intake? Food Nutr Res. 2021;65. doi: 10.29219/fnr.v65.7584.PubMedUsed to support: Analysis of 96 seaweed products on the Norwegian market: the 14 seaweed-containing dietary supplements supplied 5 to 5,600 micrograms of iodine per daily dose, and for 54 of all products one portion or dose would exceed the tolerable upper intake level. Labeling of species and iodine content was inadequate or inaccurate for several products.
- Exposure to arsenolipids and inorganic arsenic from marine-sourced dietary supplements. Chemosphere. 2022;296:133930. doi: 10.1016/j.chemosphere.2022.133930.PubMedUsed to support: Analysis of 32 marine-sourced supplements: seaweed-based products were among those with the highest total arsenic (above 1,000 ng/g), inorganic arsenic was detectable only in the seaweed products, and one seaweed product contained 8,900 ng/g of inorganic arsenic.
- Fucoidan production: Approval key challenges and opportunities. Carbohydr Polym. 2019;211:289-297. doi: 10.1016/j.carbpol.2019.01.105.PubMedUsed to support: Review explaining that fucoidan is not one uniform molecule: its structure is heterogeneous, extracts can carry co-extracted contaminants, and these problems have held back reproducible, quality-controlled production and drug approval. Supports the point that fucoidan products differ by source and process.